Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

Fig. 2

Kaplan–Meier estimates of PFS and OS according to MGMT promoter methylation status determined by HRM, MSP, and PSQ. Kaplan–Meier estimates for PFS and OS of 65 high-grade glioma patients. PFS of patients with unmethylated and methylated MGMT status, determined by HRM (a), MSP (b), and PSQ (c). OS of patients with unmethylated and methylated MGMT status, determined by HRM (d), MSP (e), and PSQ (f). Significance levels were determined by the log-rank test. U unmethylated; M methylated MGMT promoter

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us